Health care has long been an attractive sector for investors, but capital isn’t flowing evenly. While late-stage drug development and established treatments usually land the biggest checks, early diagnostics, preventive care, and pioneering therapies too often are left behind. Barriers including long development timelines, complex regulations, and unpredictable withdrawals may deter institutional investors wary of venture risk. How can innovative financing mechanisms help address these challenges and channel more capital into underfunded segments? What strategies can investors adopt to balance risk and return amid shifting valuations and evolving market conditions? And for long-term investors, do board tailwinds truly set the stage for sustainable returns, or are the risks still too significant to ignore?